JW Holdings Corporation (096760.KS)
KRW 3045.0
(0.0%)
KRW 3045.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 827.51 Billion KRW | 0.39% |
| 2022 | 824.31 Billion KRW | 8.33% |
| 2021 | 760.95 Billion KRW | -3.58% |
| 2020 | 789.22 Billion KRW | -11.51% |
| 2019 | 891.84 Billion KRW | 1.97% |
| 2018 | 874.63 Billion KRW | -10.44% |
| 2017 | 976.64 Billion KRW | 6.27% |
| 2016 | 919.03 Billion KRW | 13.1% |
| 2015 | 812.55 Billion KRW | -1.4% |
| 2014 | 824.06 Billion KRW | 5.86% |
| 2013 | 778.41 Billion KRW | -10.7% |
| 2012 | 871.66 Billion KRW | 2.77% |
| 2011 | 848.16 Billion KRW | 15.12% |
| 2010 | 736.77 Billion KRW | 50.6% |
| 2009 | 489.21 Billion KRW | 14.27% |
| 2008 | 428.09 Billion KRW | 25.85% |
| 2007 | 340.16 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 833.84 Billion KRW | 0.77% |
| 2024 Q2 | 813.35 Billion KRW | -2.46% |
| 2023 Q4 | 827.51 Billion KRW | -6.04% |
| 2023 Q3 | 880.66 Billion KRW | 2.48% |
| 2023 Q2 | 859.34 Billion KRW | -3.85% |
| 2023 FY | 827.51 Billion KRW | 0.39% |
| 2023 Q1 | 893.8 Billion KRW | 8.43% |
| 2022 Q2 | 815.8 Billion KRW | 3.95% |
| 2022 Q3 | 816.92 Billion KRW | 0.14% |
| 2022 Q4 | 824.31 Billion KRW | 0.9% |
| 2022 Q1 | 784.83 Billion KRW | 3.14% |
| 2022 FY | 824.31 Billion KRW | 8.33% |
| 2021 FY | 760.95 Billion KRW | -3.58% |
| 2021 Q3 | 746.16 Billion KRW | 0.21% |
| 2021 Q2 | 744.59 Billion KRW | -2.19% |
| 2021 Q1 | 761.29 Billion KRW | -3.54% |
| 2021 Q4 | 760.95 Billion KRW | 1.98% |
| 2020 Q4 | 789.22 Billion KRW | -9.03% |
| 2020 Q1 | 893.95 Billion KRW | 0.24% |
| 2020 FY | 789.22 Billion KRW | -11.51% |
| 2020 Q2 | 871.15 Billion KRW | -2.55% |
| 2020 Q3 | 867.54 Billion KRW | -0.41% |
| 2019 Q1 | 878.11 Billion KRW | 0.4% |
| 2019 Q3 | 844.87 Billion KRW | -2.1% |
| 2019 FY | 891.84 Billion KRW | 1.97% |
| 2019 Q2 | 863 Billion KRW | -1.72% |
| 2019 Q4 | 891.84 Billion KRW | 5.56% |
| 2018 Q4 | 874.63 Billion KRW | -3.21% |
| 2018 Q3 | 903.69 Billion KRW | -5.96% |
| 2018 Q2 | 960.96 Billion KRW | -3.11% |
| 2018 Q1 | 991.86 Billion KRW | 1.56% |
| 2018 FY | 874.63 Billion KRW | -10.44% |
| 2017 Q2 | 964 Billion KRW | -2.24% |
| 2017 Q4 | 976.64 Billion KRW | -0.92% |
| 2017 FY | 976.64 Billion KRW | 6.27% |
| 2017 Q3 | 985.71 Billion KRW | 2.25% |
| 2017 Q1 | 986.06 Billion KRW | 7.29% |
| 2016 Q3 | 872.97 Billion KRW | 2.14% |
| 2016 FY | 919.03 Billion KRW | 13.1% |
| 2016 Q1 | 844.7 Billion KRW | 3.96% |
| 2016 Q4 | 919.03 Billion KRW | 5.28% |
| 2016 Q2 | 854.67 Billion KRW | 1.18% |
| 2015 Q4 | 812.55 Billion KRW | -3.69% |
| 2015 FY | 812.55 Billion KRW | -1.4% |
| 2015 Q3 | 843.64 Billion KRW | 1.31% |
| 2015 Q2 | 832.7 Billion KRW | 1.32% |
| 2015 Q1 | 821.87 Billion KRW | -0.27% |
| 2014 Q4 | 824.06 Billion KRW | 1.76% |
| 2014 Q3 | 809.82 Billion KRW | 0.86% |
| 2014 FY | 824.06 Billion KRW | 5.86% |
| 2014 Q1 | 805.8 Billion KRW | 3.52% |
| 2014 Q2 | 802.95 Billion KRW | -0.35% |
| 2013 Q3 | 772.95 Billion KRW | 3.59% |
| 2013 Q4 | 778.41 Billion KRW | 0.71% |
| 2013 FY | 778.41 Billion KRW | -10.7% |
| 2013 Q1 | 907.06 Billion KRW | 4.06% |
| 2013 Q2 | 746.17 Billion KRW | -17.74% |
| 2012 FY | 871.66 Billion KRW | 2.77% |
| 2012 Q4 | 871.66 Billion KRW | 0.0% |
| 2011 Q3 | 55.53 Billion KRW | 27.57% |
| 2011 Q1 | 52.37 Billion KRW | 0.0% |
| 2011 Q2 | 43.52 Billion KRW | -16.89% |
| 2011 FY | 848.16 Billion KRW | 15.12% |
| 2010 Q3 | 73.79 Billion KRW | 6.53% |
| 2010 Q2 | 69.27 Billion KRW | -1.04% |
| 2010 Q1 | 70 Billion KRW | 0.0% |
| 2010 FY | 736.77 Billion KRW | 50.6% |
| 2009 Q3 | 51.6 Billion KRW | 29.47% |
| 2009 Q1 | 23.74 Billion KRW | 0.0% |
| 2009 FY | 489.21 Billion KRW | 14.27% |
| 2009 Q2 | 39.85 Billion KRW | 67.84% |
| 2008 Q1 | 9.1 Billion KRW | 0.0% |
| 2008 Q2 | 12.69 Billion KRW | 39.4% |
| 2008 FY | 428.09 Billion KRW | 25.85% |
| 2008 Q3 | 13.73 Billion KRW | 8.16% |
| 2007 Q3 | 14.47 Billion KRW | 0.0% |
| 2007 FY | 340.16 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -962.849% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 11.001% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | -17.029% |
| HANDOK Inc. | 449.7 Billion KRW | -84.011% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -865.925% |
| Yuhan Corporation | 712.33 Billion KRW | -16.168% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | -30.954% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -5106.282% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 2.854% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -1445.924% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -301.948% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -1000.839% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -459.908% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -1075.421% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -962.849% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -2171.122% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -229.488% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -274.94% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -89.364% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | -41.023% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -117.997% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -943.501% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -1082.706% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -240.746% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -150.538% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -962.849% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -68.874% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 3.557% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -117.997% |
| Yuhan Corporation | 712.33 Billion KRW | -16.168% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -73.188% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -504.162% |
| Suheung Co., Ltd. | 516.66 Billion KRW | -60.163% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -117.997% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -435.481% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -819.812% |
| CKD Bio Corp. | 170.76 Billion KRW | -384.603% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -239.514% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -424.881% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1823.589% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -943.501% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | -30.828% |
| Boryung Corporation | 373.1 Billion KRW | -121.788% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -297.465% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -301.948% |
| JW Lifescience Corporation | 96.44 Billion KRW | -758.029% |